SEC Form 4 · accession 0001209191-17-065247

Denali Therapeutics Inc. · DNLI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Dec 12, 2017

Accepted (ET)

Dec 12, 2017 · 5:40 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001714899

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3,F4	Dec 12, 2017	C	10,756,249	—	A	11,068,749	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A-1 Preferred Stock^F4,F1	—	Dec 12, 2017	C	10,068,749	D	—	—	Common Stock	10,068,749	I
Series A-2 Preferred Stock^F4,F2	—	Dec 12, 2017	C	375,000	D	—	—	Common Stock	375,000	I
Series B-1 Preferred Stock^F4,F3	—	Dec 12, 2017	C	312,500	D	—	—	Common Stock	312,500	I

F1The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F2The Series A-2 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F3The Series B-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F4The shares are held of record by ARCH Venture Fund VIII, L.P., or ARCH Venture Fund VIII. The Reporting Person is a managing director of ARCH Venture Partners VIII, L.P., the general partner of ARCH Venture Fund VIII, and shares voting and investment control with respect to these shares. The Reporting Person disclaims beneficial ownership of all shares held by ARCH Venture Fund VIII except to the extent of any pecuniary interest therein.